滤泡性淋巴瘤 (FL) 是一种惰性非霍奇金淋巴瘤，其自然史中复发和难治性逐渐增加，中位生存期约为 18-20 年。抗 CD20 单克隆抗体的出现改变了 FL 治疗算法，提高了无进展生存期。 T 细胞依赖性双特异性抗体 (BsAb) 代表了一种新兴的抗 FL 药物类别。在这篇综述中，我们使用关键词从主要数据库（PubMed、Medline、Medscape、ASCO、ESMO）中选择了 2021 年 1 月至 2024 年 6 月期间的论文“mosunetuzumab”和“滤泡性淋巴瘤”概述了 mosunetuzumab-axgb（一种开创性的 BsAb）。对其作用机制、功效、安全性和未来前景进行了分析。Mosunetuzumab 具有定向 T 细胞介导的细胞毒性，并允许逐步给药以减少细胞因子释放综合征等不良事件，并具有良好的耐受性。与此同时，它还改善了不断发展的 FL 管理领域的结果，即使是在 CAR-T 后的 FL 患者中也是如此。需要探索预后因素和靶向耐药机制。

Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma that shows a progressive increase in relapses and refractory in its natural history and a median survival of approximately 18-20 years. The advent of anti-CD20 monoclonal antibodies has changed the FL therapeutic algorithm, with an increase in progression-free survival. T-cell-dependent bispecific antibodies (BsAbs) represent an emerging drug class against FL.In this review, we selected papers from the principal databases (PubMed, Medline, Medscape, ASCO, ESMO) between January 2021 and June 2024, using the keywords 'mosunetuzumab' and 'follicular lymphoma' to provide an overview of mosunetuzumab-axgb, a pioneering BsAb. Its mechanism of action, efficacy, safety, and future perspectives were analyzed.Mosunetuzumab grants a directing T-cell mediated cytotoxicity and allows a step-up dosing that reduces adverse events, such as cytokine release syndrome, with promising tolerability. At the same time, it improves outcomes in the evolving landscape of FL management, even in post-CAR-T FL patients. Prognostic factors and targetable mechanisms of resistance need to be explored.